From the Journals

Managing pediatric heme/onc departments during the pandemic


 

FROM THE LANCET HAEMATOLOGY

Caring for patients with COVID-19

For inpatients diagnosed with COVID-19, Dr. He and colleagues recommended the following:

  • Prioritize COVID-19 treatment for children with primary disease remission.
  • For children not in remission, prioritize treatment for critical patients.
  • Isolated patients should be treated for COVID-19, and their chemotherapy should be temporarily suspended or reduced in intensity..

Dr. He and colleagues noted that, by following these recommendations for infection prevention, they had no cases of COVID-19 among children in their hematology/oncology departments. However, the authors said the recommendations “could fail to some extent” based on “differences in medical resources, health care settings, and the policy of the specific government.”

The authors said their recommendations should be updated continuously as new information and clinical evidence emerges.

Dr. He and colleagues reported having no conflicts of interest.

SOURCE: He Y et al. Lancet Haematol. doi: 10/1016/s2352-3026(20)30104-6.

Pages

Recommended Reading

Maintaining cancer care in the face of COVID-19
MDedge Hematology and Oncology
No staff COVID-19 diagnoses after plan at Chinese cancer center
MDedge Hematology and Oncology
Advice from the front lines: How cancer centers can cope with COVID-19
MDedge Hematology and Oncology
Flu activity down from its third peak of the season, COVID-19 still a factor
MDedge Hematology and Oncology
‘Brutal’ plan to restrict palliative radiation during pandemic
MDedge Hematology and Oncology
Novel acne drug now under review at the FDA
MDedge Hematology and Oncology
AAP issues guidance on managing infants born to mothers with COVID-19
MDedge Hematology and Oncology
Many children with COVID-19 don’t have cough or fever
MDedge Hematology and Oncology
‘The kids will be all right,’ won’t they?
MDedge Hematology and Oncology
Conducting cancer trials amid the COVID-19 pandemic
MDedge Hematology and Oncology